Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free PBH Stock Alerts

Prestige Consumer Healthcare (PBH) Financials

Prestige Consumer Healthcare logo
$52.48 +1.27 (+2.48%)
As of 08/28/2026 03:58 PM Eastern
Compare
Annual Income Statements for Prestige Consumer Healthcare

Annual Income Statements for Prestige Consumer Healthcare

This table shows Prestige Consumer Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 100 69 2,422 -36 142 165 205 -82 209 215 190
Consolidated Net Income / (Loss)		 100 69 340 -36 142 165 205 -82 209 215 190
Net Income / (Loss) Continuing Operations		 100 69 2,422 -36 142 165 205 -82 209 215 190
Total Pre-Tax Income 		157 111 107 -38 191 204 262 -94 276 284 257
Total Operating Income		 260 206 215 68 291 297 330 -22 342 337 309
Total Gross Profit		 467 500 577 556 552 547 621 625 624 634 596
Total Revenue		 806 882 3,124 976 963 943 1,087 1,128 1,125 1,138 1,089
Operating Revenue		 803 882 1,041 976 963 943 1,087 1,128 1,125 1,138 1,089
Total Cost of Revenue		 339 382 465 420 411 396 466 502 501 503 493
Operating Cost of Revenue		 339 382 465 420 411 396 466 502 501 503 493
Total Operating Expenses		 207 295 361 488 261 250 291 648 282 298 286
Selling, General & Admin Expense		 72 89 85 90 89 83 107 107 106 108 116
Marketing Expense		 111 128 147 143 147 141 157 145 153 156 149
Depreciation Expense		 24 25 28 27 25 24 25 25 23 21 21
Impairment Charge		 0.00 0.00 100 229 - 2.43 1.06 370 0.00 12 0.00
Total Other Income / (Expense), net		 -103 -95 -108 -106 -100 -93 -67 -72 -66 -53 -52
Interest Expense		 103 95 109 105 98 95 66 69 67 48 42
Other Income / (Expense), net		 - -0.03 0.39 -0.48 -1.63 1.37 -1.05 -2.34 0.76 -4.95 -9.57
Income Tax Expense		 57 41 -232 -2.26 49 39 57 -12 67 70 67
Basic Earnings per Share		 $1.89 $1.31 $6.40 ($0.69) $2.81 $3.28 $4.09 ($1.65) $4.21 $4.32 $3.93
Weighted Average Basic Shares Outstanding		 52.75M 52.98M 53.10M 52.07M 50.72M 50.21M 50.26M 49.89M 49.76M 49.70M 48.46M
Diluted Earnings per Share		 $1.88 $1.30 $6.34 ($0.69) $2.78 $3.25 $4.04 ($1.65) $4.17 $4.29 $3.91
Weighted Average Diluted Shares Outstanding		 53.14M 53.36M 53.53M 52.07M 51.14M 50.61M 50.84M 49.89M 50.18M 50.08M 48.72M
Weighted Average Basic & Diluted Shares Outstanding		 52.90M 53M 53.10M 51.90M 50.09M 49.91M 50.28M 49.69M 49.92M 49.41M 47.37M

Quarterly Income Statements for Prestige Consumer Healthcare

This table shows Prestige Consumer Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 Q1 2027
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 53 49 49 54 61 50 47 42 47 54 29
Consolidated Net Income / (Loss)		 53 49 49 54 61 50 47 42 47 54 29
Net Income / (Loss) Continuing Operations		 53 49 49 54 61 50 47 42 47 54 29
Total Pre-Tax Income 		70 67 58 72 80 74 62 69 62 65 39
Total Operating Income		 87 82 72 84 92 88 72 80 82 75 53
Total Gross Profit		 158 152 146 157 161 170 140 152 157 146 136
Total Revenue		 283 277 267 284 290 297 250 274 283 282 266
Operating Revenue		 283 277 267 284 290 297 250 274 283 282 266
Total Cost of Revenue		 125 125 121 126 129 127 109 123 126 135 130
Operating Cost of Revenue		 125 125 121 126 129 127 109 123 126 135 130
Total Operating Expenses		 71 70 74 73 69 82 69 72 75 71 84
Selling, General & Admin Expense		 26 26 29 26 26 27 28 28 30 30 43
Marketing Expense		 39 38 39 41 38 37 35 39 40 35 35
Depreciation Expense		 5.64 5.68 5.70 5.57 4.96 5.06 5.18 5.17 5.15 5.44 5.70
Total Other Income / (Expense), net		 -17 -15 -14 -13 -12 -14 -9.98 -11 -21 -11 -14
Interest & Investment Income		 - - - - - - -10 - - - -14
Other Income / (Expense), net		 -0.68 0.43 -0.50 -0.40 -0.35 -3.71 0.22 -0.50 -10 0.71 -0.03
Income Tax Expense		 17 18 9.35 17 19 24 14 27 15 11 9.36
Basic Earnings per Share		 $1.07 $0.99 $0.98 $1.10 $1.23 $1.01 $0.96 $0.86 $0.98 $1.13 $0.61
Weighted Average Basic Shares Outstanding		 49.74M 49.76M 49.89M 49.65M 49.60M 49.70M 49.48M 49.03M 47.88M 48.46M 47.46M
Diluted Earnings per Share		 $1.06 $0.98 $0.98 $1.09 $1.22 $1.00 $0.95 $0.86 $0.97 $1.13 $0.61
Weighted Average Diluted Shares Outstanding		 50.13M 50.18M 50.27M 50.00M 49.99M 50.08M 49.83M 49.26M 48.09M 48.72M 47.60M
Weighted Average Basic & Diluted Shares Outstanding		 49.65M 49.92M 49.56M 49.41M 49.54M 49.41M 49.21M 48.08M 47.32M 47.37M 47.37M

Annual Cash Flow Statements for Prestige Consumer Healthcare

This table details how cash moves in and out of Prestige Consumer Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 5.91 15 -9.31 -5.02 67 -62 -5.12 31 -12 51 -34
Net Cash From Operating Activities		 176 149 210 189 217 236 260 230 249 252 258
Net Cash From Continuing Operating Activities		 176 149 210 189 217 236 260 230 249 252 258
Net Income / (Loss) Continuing Operations		 100 69 340 -36 142 165 205 -82 209 215 190
Consolidated Net Income / (Loss)		 100 69 340 -36 142 165 205 -82 209 215 190
Depreciation Expense		 24 26 33 32 29 30 32 33 31 30 31
Amortization Expense		 8.99 8.63 6.74 5.92 3.81 4.98 4.23 4.36 5.24 1.75 1.80
Non-Cash Adjustments To Reconcile Net Income		 20 64 115 236 11 16 13 383 13 25 21
Changes in Operating Assets and Liabilities, net		 24 -19 -285 -49 31 20 5.48 -108 -9.63 -20 13
Net Cash From Investing Activities		 -223 -695 -12 55 -17 -22 -257 -12 -20 -17 -137
Net Cash From Continuing Investing Activities		 -223 -695 -12 55 -17 -22 -257 -12 -20 -17 -137
Purchase of Property, Plant & Equipment		 -3.57 -2.98 -13 -10 -15 -22 -9.64 -7.78 -9.55 -8.22 -11
Acquisitions		 -227 -804 0.00 0.00 -2.76 0.00 - -3.80 -11 -8.25 -124
Other Investing Activities, net		 - - 0.97 0.00 0.75 0.00 -247 - 0.00 -0.98 -1.93
Net Cash From Financing Activities		 52 561 -209 -249 -131 -279 -7.57 -186 -241 -182 -156
Net Cash From Continuing Financing Activities		 52 561 -209 -249 -131 -279 -7.57 -186 -241 -182 -156
Repayment of Debt		 -498 -979 -490 -245 -575 -883 -691 -155 -226 -135 -40
Repurchase of Common Equity		 - 0.00 0.00 -50 -57 -12 0.00 -50 -25 -52 -156
Issuance of Debt		 545 1,537 280 45 500 615 682 20 0.00 0.00 40
Other Financing Activities, net		 4.47 2.60 0.55 0.65 -0.13 0.17 1.54 -0.85 9.75 4.43 0.47
Effect of Exchange Rate Changes		 0.50 - 1.10 -0.41 -1.89 3.60 - -0.98 0.18 - 1.26
Cash Interest Paid		 79 85 99 98 92 80 61 54 63 48 44
Cash Income Taxes Paid		 15 48 24 33 31 34 47 41 60 52 46

Quarterly Cash Flow Statements for Prestige Consumer Healthcare

This table details how cash moves in and out of Prestige Consumer Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 Q1 2027
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 3.55 -17 -12 17 -0.67 47 42 -20 -57 1.50 25
Net Cash From Operating Activities		 71 67 55 70 65 62 79 57 78 43 71
Net Cash From Continuing Operating Activities		 71 67 55 70 65 62 79 57 78 43 71
Net Income / (Loss) Continuing Operations		 53 49 49 54 61 50 47 42 47 54 29
Consolidated Net Income / (Loss)		 53 49 49 54 61 50 47 42 47 54 29
Depreciation Expense		 7.65 7.84 8.12 7.93 6.87 7.25 7.67 7.66 7.59 8.35 8.75
Amortization Expense		 1.42 1.51 0.45 0.43 0.43 0.44 0.44 0.45 0.45 0.46 3.31
Non-Cash Adjustments To Reconcile Net Income		 7.66 3.55 3.87 2.05 2.81 17 3.71 1.91 13 2.71 4.18
Changes in Operating Assets and Liabilities, net		 1.70 4.54 -6.74 5.02 -6.05 -13 20 5.26 10 -23 25
Net Cash From Investing Activities		 -4.50 -15 -2.13 -2.03 -9.82 -3.48 -1.94 -2.93 -129 -3.41 -1,064
Net Cash From Continuing Investing Activities		 -4.50 -15 -2.13 -2.03 -9.82 -3.48 -1.94 -2.93 -129 -3.41 -1,064
Purchase of Property, Plant & Equipment		 -2.00 -3.14 -1.15 -2.03 -1.57 -3.48 -0.84 -2.10 -3.03 -5.21 -3.70
Acquisitions		 - - - - - - 0.00 - - 1.80 -1,045
Divestitures		 - - - - - - -1.10 - - - -15
Net Cash From Financing Activities		 -65 -68 -66 -51 -54 -11 -36 -75 -6.73 -38 1,018
Net Cash From Continuing Financing Activities		 -65 -68 -66 -51 -54 -11 -36 -75 -6.73 -38 1,018
Repayment of Debt		 -66 -75 -35 -40 -60 - 0.00 - -0.25 -40 -24
Repurchase of Common Equity		 - - -26 -12 -2.40 -11 -35 -75 -46 -0.69 0.00
Issuance of Debt		 - - - - - - 0.00 - - - 1,045
Other Financing Activities, net		 0.93 6.56 -4.55 0.62 8.54 -0.18 -1.51 0.05 -0.67 2.59 -2.58
Other Net Changes in Cash		 - - - - - - 0.83 - - - -0.25
Cash Interest Paid		 16 14 14 12 12 10 12 10 11 11 11
Cash Income Taxes Paid		 13 21 3.66 15 15 19 3.25 22 12 9.06 1.99

Annual Balance Sheets for Prestige Consumer Healthcare

This table presents Prestige Consumer Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets		 2,949 3,911 3,761 3,441 3,514 3,429 3,671 3,354 3,318 3,402 3,494
Total Current Assets		 249 334 303 301 366 270 293 392 375 448 431
Cash & Equivalents		 27 42 33 28 95 32 27 58 46 98 64
Accounts Receivable		 95 137 141 149 151 115 139 167 177 194 192
Inventories, net		 91 116 119 120 116 115 120 162 139 148 159
Prepaid Expenses		 25 40 12 4.74 4.35 7.90 6.41 4.12 13 8.44 17
Plant, Property, & Equipment, net		 16 51 53 51 56 70 71 70 77 75 122
Total Noncurrent Assets		 2,684 3,526 3,405 3,089 3,092 3,089 3,306 2,892 2,867 2,879 2,941
Noncurrent Note & Lease Receivables		 - - - 0.00 5.84 8.99 6.86 4.20 1.54 25 22
Goodwill		 360 615 620 579 575 578 579 528 528 527 581
Intangible Assets		 2,323 2,904 2,781 2,507 2,479 2,476 2,697 2,342 2,321 2,295 2,300
Other Noncurrent Operating Assets		 1.32 7.45 3.57 3.13 32 27 24 18 17 32 39
Total Liabilities & Shareholders' Equity		 2,949 3,911 3,761 3,441 3,514 3,429 3,671 3,354 3,318 3,402 3,494
Total Liabilities		 2,204 3,089 2,582 2,345 2,343 2,071 2,093 1,907 1,663 1,567 1,607
Total Current Liabilities		 107 162 123 127 150 122 143 161 117 107 121
Short-Term Debt		 - - - - - - - - - - 0.00
Accounts Payable		 38 70 61 57 62 46 56 63 39 19 23
Accrued Expenses		 60 84 52 61 71 61 74 73 56 63 73
Dividends Payable		 8.66 8.13 9.71 9.76 9.91 6.31 4.44 16 16 16 16
Other Current Liabilities		 - - - 0.00 6.83 8.45 9.11 9.76 6.15 8.54 9.57
Total Noncurrent Liabilities		 2,098 2,927 2,459 2,218 2,193 1,949 1,950 1,746 1,546 1,461 1,486
Long-Term Debt		 1,625 2,194 1,993 1,799 1,730 1,480 1,477 1,346 1,126 992 994
Capital Lease Obligations		 - - - 0.00 30 27 21 12 7.70 43 39
Noncurrent Deferred & Payable Income Tax Liabilities		 470 715 443 400 408 434 445 380 404 420 447
Other Noncurrent Operating Liabilities		 2.84 18 23 20 25 8.61 7.48 8.17 9.19 5.39 5.58
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 744 823 1,179 1,096 1,171 1,358 1,578 1,447 1,655 1,835 1,888
Total Preferred & Common Equity		 744 823 1,179 1,096 1,171 1,358 1,578 1,447 1,655 1,835 1,888
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 744 823 1,179 1,096 1,171 1,358 1,578 1,447 1,655 1,835 1,888
Common Stock		 446 459 469 480 489 500 516 536 568 594 609
Retained Earnings		 327 397 736 702 844 1,009 1,214 1,132 1,341 1,556 1,746
Treasury Stock		 -5.16 -6.59 -7.67 -60 -118 -131 -134 -189 -220 -277 -439
Accumulated Other Comprehensive Income / (Loss)		 -24 -26 -19 -26 -44 -20 -19 -32 -34 -38 -28

Quarterly Balance Sheets for Prestige Consumer Healthcare

This table presents Prestige Consumer Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026 Q1 2027
Period end date 12/31/2022 6/30/2023 9/30/2023 12/31/2023 6/30/2024 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025 6/30/2026
Total Assets		 3,750 3,346 3,333 3,340 3,308 3,317 3,329 3,432 3,442 3,495 4,569
Total Current Assets		 409 392 388 394 369 381 377 481 497 433 497
Cash & Equivalents		 86 55 60 64 34 52 51 140 119 62 89
Accounts Receivable		 157 158 158 174 172 164 167 168 199 190 187
Inventories, net		 159 170 161 149 152 156 152 153 159 164 190
Prepaid Expenses		 6.89 9.38 8.39 7.25 11 9.40 7.50 19 20 17 30
Plant, Property, & Equipment, net		 70 70 71 70 75 75 74 74 73 128 117
Total Noncurrent Assets		 3,271 2,884 2,874 2,876 2,863 2,861 2,879 2,877 2,872 2,933 3,955
Noncurrent Note & Lease Receivables		 4.86 3.54 2.87 2.21 0.88 0.21 4.94 24 23 23 21
Goodwill		 577 527 527 528 528 529 527 528 528 581 651
Intangible Assets		 2,670 2,336 2,328 2,329 2,318 2,317 2,311 2,295 2,291 2,302 3,243
Other Noncurrent Operating Assets		 20 17 16 17 16 15 36 30 29 28 39
Total Liabilities & Shareholders' Equity		 3,750 3,346 3,333 3,340 3,308 3,317 3,329 3,432 3,442 3,495 4,569
Total Liabilities		 2,063 1,865 1,797 1,739 1,627 1,585 1,541 1,576 1,617 1,665 2,652
Total Current Liabilities		 160 147 130 127 114 107 103 110 135 140 154
Short-Term Debt		 - - - - - - - - - - 10
Accounts Payable		 64 58 44 39 40 31 20 22 42 43 37
Accrued Expenses		 71 65 60 65 55 57 61 64 68 73 79
Dividends Payable		 15 15 16 15 15 16 15 15 16 15 18
Other Current Liabilities		 9.67 9.46 9.61 7.84 4.45 2.65 6.92 8.60 8.62 8.63 9.71
Total Noncurrent Liabilities		 1,903 1,718 1,667 1,612 1,513 1,478 1,439 1,466 1,483 1,526 2,498
Long-Term Debt		 1,424 1,317 1,263 1,199 1,091 1,052 992 993 993 1,034 2,007
Capital Lease Obligations		 14 9.16 0.22 6.33 7.20 0.13 28 41 39 37 36
Noncurrent Deferred & Payable Income Tax Liabilities		 456 384 388 397 409 415 413 427 445 449 449
Other Noncurrent Operating Liabilities		 8.87 8.18 16 8.92 5.14 12 5.03 5.41 5.38 5.75 5.59
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,687 1,480 1,536 1,601 1,681 1,732 1,788 1,855 1,825 1,829 1,917
Total Preferred & Common Equity		 1,687 1,480 1,536 1,601 1,681 1,732 1,788 1,855 1,825 1,829 1,917
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,687 1,480 1,536 1,601 1,681 1,732 1,788 1,855 1,825 1,829 1,917
Common Stock		 533 547 553 557 573 577 589 601 603 606 613
Retained Earnings		 1,372 1,185 1,239 1,292 1,390 1,445 1,506 1,603 1,645 1,692 1,775
Treasury Stock		 -189 -220 -220 -220 -252 -263 -266 -316 -392 -439 -442
Accumulated Other Comprehensive Income / (Loss)		 -29 -32 -36 -29 -31 -27 -40 -32 -32 -30 -30

Annual Metrics And Ratios for Prestige Consumer Healthcare

This table displays calculated financial ratios and metrics derived from Prestige Consumer Healthcare's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 47,318,730.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 47,318,730.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 4.02
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 12.82% 9.40% 254.12% -68.76% -1.31% -2.04% 15.21% 3.76% -0.21% 1.10% -4.31%
EBITDA Growth		 24.54% -18.07% 6.66% -59.10% 207.78% 3.59% 9.37% -96.65% 2,997.73% -4.05% -8.48%
EBIT Growth		 24.74% -21.01% 4.99% -68.95% 331.96% 3.19% 10.07% -107.53% 1,486.55% -3.31% -9.64%
NOPAT Growth		 29.83% -22.19% 430.74% -93.08% 358.64% 10.72% 7.59% -106.08% 1,755.14% -2.07% -10.09%
Net Income Growth		 27.66% -30.54% 389.33% -110.54% 497.43% 15.74% 24.71% -140.07% 354.34% 2.52% -11.33%
EPS Growth		 26.17% -30.85% 387.69% -110.88% 502.90% 16.91% 24.31% -140.84% 352.73% 2.88% -8.86%
Operating Cash Flow Growth		 12.83% -15.68% 41.32% -9.91% 14.71% 8.51% 10.32% -11.62% 8.36% 1.04% 2.43%
Free Cash Flow Firm Growth		 98.94% -8,194.20% 202.86% -38.25% -22.51% -0.02% -81.99% 516.93% -4.14% -15.06% -35.20%
Invested Capital Growth		 7.87% 26.86% 5.57% -8.64% -1.07% -0.26% 7.53% -9.52% -0.14% 1.11% 3.00%
Revenue Q/Q Growth		 2.26% 3.86% 204.47% -72.56% 106.12% -1.69% 2.76% 1.71% -0.78% 1.75% -1.35%
EBITDA Q/Q Growth		 1.77% -4.90% -22.74% -55.68% 205.15% 2.55% 1.73% -96.69% 2,235.94% 0.13% -2.17%
EBIT Q/Q Growth		 1.57% -5.61% -25.99% -66.06% 300.47% 2.66% 1.62% -107.44% 1,820.83% 0.65% -2.76%
NOPAT Q/Q Growth		 0.02% -4.57% 7.10% -66.90% 327.49% 6.28% 2.25% -105.92% 1,890.46% -0.17% 1.44%
Net Income Q/Q Growth		 -8.96% -3.94% -13.01% -156.12% 686.53% 5.27% 8.78% -139.13% 359.50% 0.31% 2.04%
EPS Q/Q Growth		 -9.62% -3.70% -13.03% -156.10% 795.00% 5.86% 8.60% -139.57% 359.01% 0.47% 3.44%
Operating Cash Flow Q/Q Growth		 -6.50% -17.86% 28.75% -1.86% 2.49% 1.27% 1.58% -1.77% 3.29% -1.97% -6.87%
Free Cash Flow Firm Q/Q Growth		 -102.21% -589.49% 218.73% 2.22% -8.82% 4.24% 13.03% 7.14% -6.41% -6.61% -0.41%
Invested Capital Q/Q Growth		 10.46% 38.05% -2.64% -6.13% 0.08% 0.22% 0.23% -9.57% 0.00% 0.56% 0.68%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 57.95% 56.72% 18.46% 56.94% 57.34% 58.03% 57.11% 55.45% 55.49% 55.76% 54.71%
EBITDA Margin		 36.34% 27.21% 8.20% 10.73% 33.47% 35.40% 33.60% 1.09% 33.69% 31.97% 30.58%
Operating Margin		 32.29% 23.31% 6.90% 6.92% 30.23% 31.53% 30.36% -1.99% 30.43% 29.60% 28.42%
EBIT Margin		 32.29% 23.31% 6.91% 6.87% 30.07% 31.67% 30.26% -2.19% 30.50% 29.16% 27.54%
Profit (Net Income) Margin		 12.39% 7.87% 10.87% -3.67% 14.77% 17.46% 18.90% -7.30% 18.60% 18.86% 17.48%
Tax Burden Percent		 63.56% 62.60% 317.10% 94.07% 74.43% 80.68% 78.25% 87.64% 75.84% 75.51% 73.90%
Interest Burden Percent		 60.38% 53.91% 49.61% -56.78% 66.02% 68.32% 79.81% 379.44% 80.43% 85.65% 85.88%
Effective Tax Rate		 36.44% 37.40% -217.10% 0.00% 25.57% 19.32% 21.75% 0.00% 24.16% 24.49% 26.10%
Return on Invested Capital (ROIC)		 7.30% 4.83% 22.29% 1.57% 7.57% 8.44% 8.77% -0.54% 9.41% 9.17% 8.08%
ROIC Less NNEP Spread (ROIC-NNEP)		 3.15% 1.68% 5.64% -2.86% 3.27% 3.67% 5.19% -5.32% 5.24% 5.31% 4.12%
Return on Net Nonoperating Assets (RNNOA)		 7.26% 4.03% 11.65% -4.72% 4.98% 4.58% 5.23% -4.90% 4.09% 3.13% 2.15%
Return on Equity (ROE)		 14.56% 8.86% 33.94% -3.15% 12.55% 13.02% 13.99% -5.44% 13.50% 12.30% 10.22%
Cash Return on Invested Capital (CROIC)		 -0.27% -18.85% 16.87% 10.60% 8.65% 8.70% 1.51% 9.45% 9.55% 8.07% 5.12%
Operating Return on Assets (OROA)		 9.31% 5.99% 5.63% 1.86% 8.33% 8.61% 9.26% -0.70% 10.29% 9.87% 8.70%
Return on Assets (ROA)		 3.57% 2.02% 8.85% -0.99% 4.09% 4.74% 5.79% -2.34% 6.28% 6.39% 5.52%
Return on Common Equity (ROCE)		 14.56% 8.86% 33.94% -3.15% 12.55% 13.02% 13.99% -5.44% 13.50% 12.30% 10.22%
Return on Equity Simple (ROE_SIMPLE)		 13.42% 8.44% 28.81% -3.27% 12.15% 12.12% 13.02% -5.69% 12.65% 11.70% 0.00%
Net Operating Profit after Tax (NOPAT)		 165 129 683 47 217 240 258 -16 260 254 229
NOPAT Margin		 20.52% 14.60% 21.87% 4.84% 22.50% 25.44% 23.75% -1.39% 23.08% 22.35% 21.00%
Net Nonoperating Expense Percent (NNEP)		 4.15% 3.15% 16.64% 4.43% 4.31% 4.77% 3.57% 4.78% 4.17% 3.86% 3.96%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - 8.86% 7.83%
Cost of Revenue to Revenue		 42.05% 43.28% 14.88% 43.06% 42.66% 41.97% 42.89% 44.55% 44.51% 44.24% 45.29%
SG&A Expenses to Revenue		 8.98% 10.10% 2.73% 9.20% 9.25% 8.81% 9.89% 9.52% 9.43% 9.51% 10.70%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 25.66% 33.40% 11.56% 50.02% 27.11% 26.51% 26.75% 57.44% 25.06% 26.16% 26.29%
Earnings before Interest and Taxes (EBIT)		 260 206 216 67 290 299 329 -25 343 332 300
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 293 240 256 105 322 334 365 12 379 364 333
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.74 3.53 1.50 1.41 1.57 1.62 1.68 2.15 2.18 2.32 1.49
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.45 3.29 0.57 1.59 1.91 2.33 2.45 2.76 3.20 3.74 2.58
Price to Earnings (P/E)		 27.84 41.86 0.73 0.00 12.96 13.35 12.94 0.00 17.21 19.84 14.74
Dividend Yield		 0.00% 0.00% 0.00% 1.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 3.59% 2.39% 137.11% 0.00% 7.72% 7.49% 7.73% 0.00% 5.81% 5.04% 6.79%
Enterprise Value to Invested Capital (EV/IC)		 1.86 1.70 1.18 1.15 1.23 1.29 1.35 1.60 1.70 1.86 1.31
Enterprise Value to Revenue (EV/Rev)		 5.43 5.73 1.19 3.40 3.64 3.89 3.80 3.91 4.17 4.57 3.47
Enterprise Value to EBITDA (EV/EBITDA)		 14.95 21.07 14.56 31.70 10.89 11.00 11.30 360.42 12.37 14.29 11.34
Enterprise Value to EBIT (EV/EBIT)		 16.83 24.59 17.26 49.54 12.12 12.29 12.55 0.00 13.66 15.66 12.59
Enterprise Value to NOPAT (EV/NOPAT)		 26.47 39.28 5.45 70.27 16.19 15.30 15.99 0.00 18.06 20.43 16.50
Enterprise Value to Operating Cash Flow (EV/OCF)		 24.84 34.01 17.74 17.54 16.16 15.58 15.88 19.20 18.84 20.66 14.65
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 7.21 10.40 14.18 14.84 92.66 16.05 17.80 23.22 26.03
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 2.18 2.67 1.69 1.64 1.50 1.11 0.95 0.94 0.68 0.56 0.55
Long-Term Debt to Equity		 2.18 2.67 1.69 1.64 1.50 1.11 0.95 0.94 0.68 0.56 0.55
Financial Leverage		 2.30 2.40 2.06 1.65 1.52 1.25 1.01 0.92 0.78 0.59 0.52
Leverage Ratio		 4.08 4.38 3.83 3.17 3.07 2.75 2.42 2.32 2.15 1.93 1.85
Compound Leverage Factor		 2.46 2.36 1.90 -1.80 2.03 1.88 1.93 8.81 1.73 1.65 1.59
Debt to Total Capital		 68.59% 72.73% 62.84% 62.14% 60.05% 52.58% 48.69% 48.40% 40.65% 36.08% 35.37%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 68.59% 72.73% 62.84% 62.14% 60.05% 52.58% 48.69% 48.40% 40.65% 36.08% 35.37%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 31.41% 27.27% 37.16% 37.86% 39.95% 47.42% 51.31% 51.60% 59.35% 63.92% 64.63%
Debt to EBITDA		 5.55 9.14 7.78 17.17 5.46 4.51 4.10 110.91 2.99 2.85 3.10
Net Debt to EBITDA		 5.45 8.96 7.66 16.91 5.17 4.41 4.03 106.13 2.87 2.58 2.91
Long-Term Debt to EBITDA		 5.55 9.14 7.78 17.17 5.46 4.51 4.10 110.91 2.99 2.85 3.10
Debt to NOPAT		 9.82 17.04 2.92 38.06 8.12 6.28 5.80 -86.51 4.36 4.07 4.52
Net Debt to NOPAT		 9.66 16.72 2.87 37.48 7.68 6.14 5.69 -82.78 4.19 3.69 4.24
Long-Term Debt to NOPAT		 9.82 17.04 2.92 38.06 8.12 6.28 5.80 -86.51 4.36 4.07 4.52
Altman Z-Score		 1.54 1.16 1.76 1.09 1.43 1.66 1.87 1.85 2.64 3.05 2.45
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.33 2.06 2.46 2.37 2.44 2.21 2.04 2.44 3.20 4.20 3.57
Quick Ratio		 1.15 1.10 1.41 1.39 1.64 1.20 1.16 1.40 1.91 2.74 2.12
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.06 -503 517 319 247 247 45 275 263 224 145
Operating Cash Flow to CapEx		 5,468.67% 5,140.80% 1,676.59% 1,806.15% 1,491.24% 1,059.24% 2,695.73% 2,951.13% 2,606.56% 3,058.31% 2,304.77%
Free Cash Flow to Firm to Interest Expense		 -0.06 -5.29 4.74 3.04 2.52 2.61 0.67 3.97 3.92 4.70 3.42
Operating Cash Flow to Interest Expense		 1.71 1.57 1.92 1.80 2.21 2.49 3.91 3.32 3.71 5.28 6.08
Operating Cash Flow Less CapEx to Interest Expense		 1.68 1.54 1.81 1.70 2.06 2.25 3.77 3.21 3.56 5.11 5.82
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.29 0.26 0.81 0.27 0.28 0.27 0.31 0.32 0.34 0.34 0.32
Accounts Receivable Turnover		 8.81 7.60 22.50 6.74 6.44 7.11 8.56 7.36 6.55 6.13 5.64
Inventory Turnover		 4.10 3.69 3.97 3.52 3.48 3.43 3.96 3.56 3.33 3.51 3.21
Fixed Asset Turnover		 55.06 26.67 60.56 18.81 17.97 14.97 15.38 15.92 15.32 15.06 11.10
Accounts Payable Turnover		 8.03 7.04 7.06 7.13 6.91 7.31 9.16 8.48 9.85 17.38 23.64
Days Sales Outstanding (DSO)		 41.45 48.00 16.22 54.18 56.72 51.30 42.65 49.58 55.75 59.52 64.74
Days Inventory Outstanding (DIO)		 88.96 98.89 91.96 103.55 104.81 106.48 92.12 102.60 109.61 103.86 113.56
Days Payable Outstanding (DPO)		 45.44 51.87 51.69 51.23 52.84 49.95 39.83 43.04 37.06 21.00 15.44
Cash Conversion Cycle (CCC)		 84.97 95.02 56.50 106.50 108.69 107.83 94.94 109.13 128.30 142.38 162.86
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2,351 2,983 3,149 2,877 2,846 2,838 3,052 2,762 2,758 2,788 2,872
Invested Capital Turnover		 0.36 0.33 1.02 0.32 0.34 0.33 0.37 0.39 0.41 0.41 0.38
Increase / (Decrease) in Invested Capital		 172 631 166 -272 -31 -7.44 214 -290 -3.73 31 84
Enterprise Value (EV)		 4,380 5,057 3,727 3,320 3,509 3,672 4,128 4,411 4,690 5,197 3,774
Market Capitalization		 2,782 2,905 1,766 1,549 1,844 2,198 2,658 3,112 3,603 4,259 2,805
Book Value per Share		 $14.11 $15.54 $22.22 $21.16 $23.30 $27.24 $31.43 $29.12 $33.34 $37.04 $39.89
Tangible Book Value per Share		 ($36.75) ($50.94) ($41.90) ($38.42) ($37.47) ($34.00) ($33.83) ($28.63) ($24.03) ($19.94) ($20.99)
Total Capital		 2,370 3,016 3,172 2,894 2,931 2,864 3,075 2,804 2,789 2,871 2,920
Total Debt		 1,625 2,194 1,993 1,799 1,760 1,506 1,497 1,357 1,134 1,036 1,033
Total Long-Term Debt		 1,625 2,194 1,993 1,799 1,760 1,506 1,497 1,357 1,134 1,036 1,033
Net Debt		 1,598 2,152 1,960 1,771 1,665 1,474 1,470 1,299 1,087 938 969
Capital Expenditures (CapEx)		 3.22 2.89 13 10 15 22 9.64 7.78 9.55 8.22 11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 115 131 148 146 121 115 123 173 212 244 247
Debt-free Net Working Capital (DFNWC)		 142 172 180 174 216 148 150 231 258 342 311
Net Working Capital (NWC)		 142 172 180 174 216 148 150 231 258 342 311
Net Nonoperating Expense (NNE)		 66 59 344 83 74 75 53 67 50 40 38
Net Nonoperating Obligations (NNO)		 1,607 2,160 1,970 1,781 1,675 1,480 1,474 1,315 1,103 954 985
Total Depreciation and Amortization (D&A)		 33 34 40 38 33 35 36 37 36 32 33
Debt-free, Cash-free Net Working Capital to Revenue		 14.28% 14.80% 4.73% 15.01% 12.57% 12.23% 11.29% 15.30% 18.80% 21.43% 22.66%
Debt-free Net Working Capital to Revenue		 17.65% 19.55% 5.77% 17.83% 22.41% 15.66% 13.79% 20.49% 22.93% 30.03% 28.53%
Net Working Capital to Revenue		 17.65% 19.55% 5.77% 17.83% 22.41% 15.66% 13.79% 20.49% 22.93% 30.03% 28.53%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.89 $1.31 $6.40 ($0.69) $2.81 $3.28 $4.09 ($1.65) $4.21 $4.32 $3.93
Adjusted Weighted Average Basic Shares Outstanding		 52.75M 52.98M 53.10M 52.07M 50.72M 50.21M 50.26M 49.89M 49.76M 49.70M 48.46M
Adjusted Diluted Earnings per Share		 $1.88 $1.30 $6.34 ($0.69) $2.78 $3.25 $4.04 ($1.65) $4.17 $4.29 $3.91
Adjusted Weighted Average Diluted Shares Outstanding		 53.14M 53.36M 53.53M 52.07M 51.14M 50.61M 50.84M 49.89M 50.18M 50.08M 48.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.69) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 52.76M 52.96M 53.07M 51.80M 50.09M 49.91M 50.28M 49.69M 49.92M 49.41M 47.37M
Normalized Net Operating Profit after Tax (NOPAT)		 165 129 221 208 217 242 259 243 260 264 229
Normalized NOPAT Margin		 20.52% 14.60% 7.07% 21.30% 22.50% 25.64% 23.83% 21.59% 23.08% 23.18% 21.00%
Pre Tax Income Margin		 19.50% 12.57% 3.43% -3.90% 19.85% 21.64% 24.15% -8.33% 24.53% 24.98% 23.65%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 2.52 2.17 1.98 0.64 2.94 3.16 4.95 -0.36 5.11 6.97 7.08
NOPAT to Interest Expense		 1.60 1.36 6.26 0.45 2.20 2.54 3.89 -0.23 3.87 5.34 5.40
EBIT Less CapEx to Interest Expense		 2.49 2.13 1.86 0.54 2.80 2.92 4.81 -0.47 4.97 6.79 6.82
NOPAT Less CapEx to Interest Expense		 1.57 1.33 6.14 0.35 2.05 2.30 3.74 -0.34 3.72 5.17 5.14
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -139.60% 39.87% 7.21% 0.00% -60.75% 11.94% 24.00% 82.12%

Quarterly Metrics And Ratios for Prestige Consumer Healthcare

This table displays calculated financial ratios and metrics derived from Prestige Consumer Healthcare's official financial filings.

Metric Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 Q1 2027
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 47,318,730.00 47,372,166.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 47,318,730.00 47,372,166.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 1.14 0.62
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 2.62% -3.11% -4.36% -0.88% 2.68% 7.05% -6.59% -3.41% -2.37% -5.03% 6.48%
EBITDA Growth		 0.25% 133.93% -15.62% -4.83% 3.88% 0.51% -0.05% -5.44% -18.58% -8.01% -19.41%
EBIT Growth		 0.13% 129.44% -17.22% -4.63% 6.34% 2.59% 0.60% -5.69% -20.87% -10.05% -27.08%
NOPAT Growth		 -0.44% 130.68% -8.38% -4.66% 5.77% -0.69% -8.90% -23.99% -11.01% 4.87% -27.88%
Net Income Growth		 2.11% 120.56% -7.90% 1.53% 15.05% 1.35% -3.26% -22.37% -23.49% 7.58% -38.53%
EPS Growth		 1.92% 120.42% -7.55% 1.87% 15.09% 2.04% -3.06% -21.10% -20.49% 13.00% -35.79%
Operating Cash Flow Growth		 30.09% 13.43% 13.91% 11.75% -8.93% -7.56% 44.25% -17.64% 20.27% -30.73% -10.41%
Free Cash Flow Firm Growth		 525.76% -31.68% -80.23% -79.51% -84.85% -54.14% -25.33% -40.28% -131.92% -170.84% -2,284.12%
Invested Capital Growth		 -9.69% -0.14% -0.24% -0.26% 0.55% 1.11% 0.18% 0.23% 2.88% 3.00% 41.03%
Revenue Q/Q Growth		 -1.25% -2.03% -3.56% 6.23% 2.30% 2.14% -15.85% 9.85% 3.40% -0.64% -5.65%
EBITDA Q/Q Growth		 -1.82% -3.45% -12.85% 15.19% 7.16% -6.57% -13.33% 8.98% -7.73% 5.56% -24.07%
EBIT Q/Q Growth		 -2.13% -4.14% -13.36% 17.32% 9.13% -7.52% -15.04% 9.99% -8.44% 5.12% -31.12%
NOPAT Q/Q Growth		 -1.37% -8.84% 0.28% 5.74% 9.42% -14.41% -8.01% -11.77% 28.10% 0.86% -36.74%
Net Income Q/Q Growth		 -0.96% -6.76% -0.79% 10.82% 12.24% -17.87% -5.31% -11.07% 10.63% 15.49% -45.90%
EPS Q/Q Growth		 -0.93% -7.55% 0.00% 11.22% 11.93% -18.03% -5.00% -9.47% 12.79% 16.49% -46.02%
Operating Cash Flow Q/Q Growth		 14.43% -6.39% -18.13% 27.43% -6.75% -4.98% 27.75% -27.24% 36.18% -45.28% 65.23%
Free Cash Flow Firm Q/Q Growth		 4.40% -82.31% 4.74% 5.88% -22.79% -46.45% 70.56% -15.33% -141.28% -18.85% -5,158.26%
Invested Capital Q/Q Growth		 0.11% 0.00% 0.08% -0.45% 0.92% 0.56% -0.83% -0.41% 3.59% 0.68% 35.78%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 55.86% 54.81% 54.66% 55.46% 55.47% 57.34% 56.24% 55.30% 55.52% 51.95% 51.25%
EBITDA Margin		 33.68% 33.19% 29.99% 32.53% 34.07% 31.16% 32.10% 31.84% 28.41% 30.19% 24.29%
Operating Margin		 30.71% 29.66% 26.97% 29.72% 31.68% 29.82% 28.76% 29.06% 29.10% 26.81% 19.77%
EBIT Margin		 30.47% 29.81% 26.78% 29.58% 31.55% 28.57% 28.85% 28.88% 25.57% 27.06% 19.75%
Profit (Net Income) Margin		 18.76% 17.86% 18.37% 19.16% 21.02% 16.91% 19.02% 15.40% 16.47% 19.15% 10.98%
Tax Burden Percent		 76.24% 73.46% 84.00% 75.88% 76.14% 67.78% 76.83% 61.06% 75.54% 83.26% 75.70%
Interest Burden Percent		 80.76% 81.52% 81.64% 85.37% 87.50% 87.30% 85.83% 87.32% 85.28% 85.00% 73.43%
Effective Tax Rate		 23.76% 26.54% 16.00% 24.12% 23.86% 32.22% 23.17% 38.94% 24.46% 16.74% 24.30%
Return on Invested Capital (ROIC)		 9.14% 8.89% 9.13% 9.10% 9.75% 8.29% 8.96% 7.16% 8.63% 8.59% 4.96%
ROIC Less NNEP Spread (ROIC-NNEP)		 8.10% 7.98% 8.16% 8.24% 8.91% 7.34% 8.19% 6.50% 7.07% 7.66% 4.23%
Return on Net Nonoperating Assets (RNNOA)		 6.22% 6.22% 6.11% 5.64% 5.63% 4.32% 4.61% 3.56% 3.92% 3.99% 3.24%
Return on Equity (ROE)		 15.36% 15.11% 15.23% 14.74% 15.39% 12.62% 13.56% 10.72% 12.55% 12.58% 8.20%
Cash Return on Invested Capital (CROIC)		 9.69% 9.55% 9.44% 9.38% 8.66% 8.07% 8.84% 8.27% 5.18% 5.12% -27.65%
Operating Return on Assets (OROA)		 9.75% 10.06% 8.96% 9.88% 10.58% 9.67% 9.59% 9.49% 8.27% 8.54% 5.46%
Return on Assets (ROA)		 6.00% 6.02% 6.15% 6.40% 7.05% 5.72% 6.32% 5.06% 5.33% 6.05% 3.03%
Return on Common Equity (ROCE)		 15.36% 15.11% 15.23% 14.74% 15.39% 12.62% 13.56% 10.72% 12.55% 12.58% 8.20%
Return on Equity Simple (ROE_SIMPLE)		 -5.04% 0.00% 12.20% 11.89% 11.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 66 60 61 64 70 60 55 49 62 63 40
NOPAT Margin		 23.41% 21.79% 22.65% 22.55% 24.12% 20.21% 22.09% 17.75% 21.99% 22.32% 14.96%
Net Nonoperating Expense Percent (NNEP)		 1.04% 0.90% 0.97% 0.86% 0.84% 0.95% 0.77% 0.66% 1.56% 0.92% 0.73%
Return On Investment Capital (ROIC_SIMPLE)		 2.36% - - - 2.49% 2.09% 1.91% 1.70% 2.15% 2.15% 1.00%
Cost of Revenue to Revenue		 44.14% 45.19% 45.34% 44.54% 44.53% 42.66% 43.76% 44.70% 44.48% 48.05% 48.75%
SG&A Expenses to Revenue		 9.20% 9.55% 10.82% 9.19% 9.02% 9.12% 11.40% 10.23% 10.47% 10.75% 16.30%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 25.15% 25.15% 27.69% 25.74% 23.80% 27.51% 27.48% 26.23% 26.42% 25.14% 31.49%
Earnings before Interest and Taxes (EBIT)		 86 83 72 84 92 85 72 79 72 76 52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 95 92 80 92 99 92 80 87 81 85 65
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.90 2.18 2.04 2.06 2.16 2.32 2.13 1.68 1.62 1.49 1.17
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.68 3.20 3.09 3.22 3.45 3.74 3.52 2.77 2.69 2.58 2.03
Price to Earnings (P/E)		 0.00 17.21 16.75 17.35 18.03 19.84 18.52 15.29 15.91 14.74 13.02
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 5.81% 5.97% 5.76% 5.55% 5.04% 5.40% 6.54% 6.29% 6.79% 7.68%
Enterprise Value to Invested Capital (EV/IC)		 1.52 1.70 1.63 1.66 1.74 1.86 1.75 1.45 1.39 1.31 1.08
Enterprise Value to Revenue (EV/Rev)		 3.69 4.17 4.04 4.12 4.32 4.57 4.32 3.59 3.60 3.47 3.81
Enterprise Value to EBITDA (EV/EBITDA)		 257.55 12.37 12.36 12.72 13.29 14.29 13.31 11.11 11.68 11.34 13.25
Enterprise Value to EBIT (EV/EBIT)		 0.00 13.66 13.71 14.11 14.64 15.66 14.57 12.17 12.89 12.59 15.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 18.06 17.71 18.22 18.95 20.43 19.42 17.04 17.63 16.50 19.73
Enterprise Value to Operating Cash Flow (EV/OCF)		 17.34 18.84 17.61 17.39 18.81 20.66 17.55 15.12 14.37 14.65 16.86
Enterprise Value to Free Cash Flow (EV/FCFF)		 14.85 17.80 17.26 17.72 20.15 23.22 19.82 17.51 27.30 26.03 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.75 0.68 0.65 0.61 0.57 0.56 0.56 0.57 0.59 0.55 1.07
Long-Term Debt to Equity		 0.75 0.68 0.65 0.61 0.57 0.56 0.56 0.57 0.59 0.55 1.07
Financial Leverage		 0.77 0.78 0.75 0.68 0.63 0.59 0.56 0.55 0.56 0.52 0.77
Leverage Ratio		 2.16 2.15 2.10 2.04 1.97 1.93 1.91 1.90 1.89 1.85 2.12
Compound Leverage Factor		 1.74 1.75 1.72 1.74 1.72 1.68 1.64 1.66 1.61 1.57 1.56
Debt to Total Capital		 42.96% 40.65% 39.52% 37.78% 36.32% 36.08% 35.79% 36.13% 36.92% 35.37% 51.73%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.26%
Long-Term Debt to Total Capital		 42.96% 40.65% 39.52% 37.78% 36.32% 36.08% 35.79% 36.13% 36.92% 35.37% 51.47%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 57.04% 59.35% 60.48% 62.22% 63.68% 63.92% 64.21% 63.87% 63.08% 64.63% 48.27%
Debt to EBITDA		 74.29 2.99 3.02 2.92 2.81 2.85 2.84 2.88 3.15 3.10 6.47
Net Debt to EBITDA		 70.37 2.87 2.92 2.78 2.67 2.58 2.46 2.55 2.96 2.91 6.19
Long-Term Debt to EBITDA		 74.29 2.99 3.02 2.92 2.81 2.85 2.84 2.88 3.15 3.10 6.44
Debt to NOPAT		 -83.12 4.36 4.32 4.19 4.00 4.07 4.15 4.42 4.75 4.52 9.64
Net Debt to NOPAT		 -78.74 4.19 4.19 3.98 3.81 3.69 3.59 3.91 4.47 4.24 9.22
Long-Term Debt to NOPAT		 -83.12 4.36 4.32 4.19 4.00 4.07 4.15 4.42 4.75 4.52 9.59
Altman Z-Score		 2.11 2.38 2.36 2.48 2.66 2.81 2.68 2.33 2.23 2.24 1.42
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.09 3.20 3.23 3.56 3.68 4.20 4.38 3.70 3.11 3.57 3.23
Quick Ratio		 1.87 1.91 1.80 2.01 2.13 2.74 2.81 2.36 1.81 2.12 1.80
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 362 64 67 71 55 29 50 42 -18 -21 -1,095
Operating Cash Flow to CapEx		 3,580.76% 2,128.76% 4,754.86% 3,443.51% 4,156.51% 1,777.75% 9,428.76% 2,734.82% 2,585.44% 822.28% 1,911.64%
Free Cash Flow to Firm to Interest Expense		 21.85 4.20 5.11 5.79 4.79 2.73 4.91 4.23 -1.64 -1.82 0.00
Operating Cash Flow to Interest Expense		 4.31 4.38 4.17 5.68 5.68 5.75 7.74 5.73 7.34 3.75 0.00
Operating Cash Flow Less CapEx to Interest Expense		 4.19 4.18 4.08 5.52 5.55 5.43 7.66 5.52 7.05 3.29 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.32 0.34 0.33 0.33 0.34 0.34 0.33 0.33 0.32 0.32 0.28
Accounts Receivable Turnover		 6.85 6.55 6.75 6.90 6.55 6.13 6.59 6.13 6.17 5.64 6.21
Inventory Turnover		 3.31 3.33 3.09 3.13 3.34 3.51 3.22 3.09 3.07 3.21 2.99
Fixed Asset Turnover		 16.21 15.32 15.31 15.25 15.54 15.06 15.02 15.00 10.94 11.10 11.57
Accounts Payable Turnover		 9.80 9.85 10.21 13.17 17.06 17.38 15.91 13.34 15.51 23.64 17.39
Days Sales Outstanding (DSO)		 53.32 55.75 54.04 52.91 55.74 59.52 55.41 59.58 59.16 64.74 58.76
Days Inventory Outstanding (DIO)		 110.38 109.61 118.11 116.47 109.13 103.86 113.34 118.00 118.74 113.56 122.04
Days Payable Outstanding (DPO)		 37.23 37.06 35.74 27.72 21.39 21.00 22.94 27.36 23.53 15.44 20.99
Cash Conversion Cycle (CCC)		 126.47 128.30 136.40 141.67 143.48 142.38 145.81 150.22 154.36 162.86 159.81
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2,758 2,758 2,760 2,748 2,773 2,788 2,765 2,754 2,853 2,872 3,900
Invested Capital Turnover		 0.39 0.41 0.40 0.40 0.40 0.41 0.41 0.40 0.39 0.38 0.33
Increase / (Decrease) in Invested Capital		 -296 -3.73 -6.61 -7.08 15 31 5.01 6.20 80 84 1,135
Enterprise Value (EV)		 4,180 4,690 4,501 4,573 4,827 5,197 4,840 3,984 3,975 3,774 4,204
Market Capitalization		 3,038 3,603 3,437 3,573 3,858 4,259 3,946 3,071 2,966 2,805 2,239
Book Value per Share		 $32.26 $33.34 $33.67 $34.94 $36.20 $37.04 $37.55 $37.08 $38.05 $39.89 $40.46
Tangible Book Value per Share		 ($25.31) ($24.03) ($23.35) ($22.48) ($21.24) ($19.94) ($19.58) ($20.21) ($21.91) ($20.99) ($41.74)
Total Capital		 2,806 2,789 2,779 2,783 2,809 2,871 2,890 2,857 2,900 2,920 3,971
Total Debt		 1,206 1,134 1,098 1,052 1,020 1,036 1,034 1,032 1,071 1,033 2,054
Total Long-Term Debt		 1,206 1,134 1,098 1,052 1,020 1,036 1,034 1,032 1,071 1,033 2,044
Net Debt		 1,142 1,087 1,064 1,000 969 938 895 913 1,008 969 1,965
Capital Expenditures (CapEx)		 2.00 3.14 1.15 2.03 1.57 3.48 0.84 2.10 3.03 5.21 3.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 203 212 220 222 224 244 231 244 231 247 264
Debt-free Net Working Capital (DFNWC)		 266 258 255 274 275 342 371 363 294 311 353
Net Working Capital (NWC)		 266 258 255 274 275 342 371 363 294 311 343
Net Nonoperating Expense (NNE)		 13 11 11 9.62 8.99 9.81 7.67 6.43 16 8.93 11
Net Nonoperating Obligations (NNO)		 1,157 1,103 1,079 1,016 985 954 910 929 1,023 985 1,983
Total Depreciation and Amortization (D&A)		 9.07 9.36 8.58 8.36 7.30 7.69 8.11 8.11 8.04 8.81 12
Debt-free, Cash-free Net Working Capital to Revenue		 17.87% 18.80% 19.80% 20.01% 20.01% 21.43% 20.65% 21.95% 20.98% 22.66% 23.92%
Debt-free Net Working Capital to Revenue		 23.48% 22.93% 22.87% 24.65% 24.56% 30.03% 33.11% 32.67% 26.63% 28.53% 31.99%
Net Working Capital to Revenue		 23.48% 22.93% 22.87% 24.65% 24.56% 30.03% 33.11% 32.67% 26.63% 28.53% 31.04%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.07 $0.99 $0.98 $1.10 $1.23 $1.01 $0.96 $0.86 $0.98 $1.13 $0.61
Adjusted Weighted Average Basic Shares Outstanding		 49.74M 49.76M 49.89M 49.65M 49.60M 49.70M 49.48M 49.03M 47.88M 48.46M 47.46M
Adjusted Diluted Earnings per Share		 $1.06 $0.98 $0.98 $1.09 $1.22 $1.00 $0.95 $0.86 $0.97 $1.13 $0.61
Adjusted Weighted Average Diluted Shares Outstanding		 50.13M 50.18M 50.27M 50.00M 49.99M 50.08M 49.83M 49.26M 48.09M 48.72M 47.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.65M 49.92M 49.56M 49.41M 49.54M 49.41M 49.21M 48.08M 47.32M 47.37M 47.37M
Normalized Net Operating Profit after Tax (NOPAT)		 66 60 61 64 70 60 55 49 62 63 40
Normalized NOPAT Margin		 23.41% 21.79% 22.65% 22.55% 24.12% 20.21% 22.09% 17.75% 21.99% 22.32% 14.96%
Pre Tax Income Margin		 24.61% 24.30% 21.87% 25.25% 27.61% 24.94% 24.76% 25.22% 21.81% 23.00% 14.50%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 5.20 5.41 5.45 6.84 8.00 7.87 7.05 7.89 6.79 6.67 0.00
NOPAT to Interest Expense		 3.99 3.96 4.61 5.21 6.11 5.57 5.40 4.85 5.84 5.50 0.00
EBIT Less CapEx to Interest Expense		 5.08 5.21 5.36 6.67 7.86 7.55 6.97 7.68 6.51 6.21 0.00
NOPAT Less CapEx to Interest Expense		 3.87 3.75 4.52 5.05 5.98 5.25 5.32 4.64 5.56 5.04 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -30.99% 11.94% 12.66% 18.35% 18.79% 24.00% 28.31% 61.49% 89.49% 82.12% 70.64%

Financials Breakdown Chart

Key Financial Trends

Prestige Consumer Healthcare’s latest results show a business undergoing a major acquisition-driven balance-sheet expansion while near-term profitability and cash generation have weakened. For the quarter ended June 30, 2026, revenue was $265.7 million, down 5.6% from $281.6 million in the prior quarter and up 6.5% from the restated year-ago quarter. However, earnings declined meaningfully as operating costs and interest expense increased.

Gross margin fell to approximately 51.2%, compared with 56.2% in Q1 2026 and 57.1% in Q1 2025. Operating margin declined to 19.8% from 28.8% a year earlier, while net margin fell to roughly 11.0% from 19.0%. Diluted EPS dropped to $0.61 from $0.95 in the restated year-ago period.

  • Operating cash flow remains substantial. Prestige generated $70.8 million in cash from operations in Q1 2027, representing approximately 2.4 times reported net income. This provides an important source of liquidity for debt service and integration spending.
  • Share count has continued to decline over the longer term. Weighted-average basic shares fell to 47.5 million from 49.5 million in Q1 2025, a reduction of roughly 4%. Although no shares were repurchased in the latest quarter, the prior buyback program has supported per-share value over time.
  • Liquidity improved in the latest quarter. Cash and equivalents increased to $89.1 million from $62.4 million in Q3 2026 and $34.3 million in Q1 2025. Current assets of $496.8 million also exceeded current liabilities of $153.8 million, producing a current ratio of approximately 3.2.
  • The acquisition could expand Prestige’s long-term revenue base. The company spent approximately $1.05 billion on acquisitions during the quarter. If the acquired brands and products are integrated successfully, they could help reverse the recent revenue stagnation and create future operating synergies.
  • Working capital was a positive contributor to operating cash flow in Q1 2027. Changes in operating assets and liabilities added $25.4 million to cash flow, compared with a $19.7 million benefit in Q1 2026. This is supportive in the short term, although investors should determine whether the improvement is recurring or acquisition-related.
  • The asset base changed sharply because of the acquisition. Total assets rose to $4.57 billion from $3.43 billion in Q1 2026, while goodwill increased to $650.8 million and intangible assets increased to $3.24 billion. These figures will need to be monitored for future impairment risk and the pace of amortization.
  • Profitability has deteriorated across the recent periods. Q1 2027 operating income fell to $52.5 million from $71.8 million in Q1 2026 and $88.4 million in Q4 2025. Selling, general and administrative expense rose 52% year over year to $43.3 million, while marketing expense remained elevated at $34.7 million.
  • Free cash flow declined. After $3.7 million of capital expenditures, estimated free cash flow was approximately $67.1 million, down from $78.2 million in Q1 2026. The decline occurred despite solid operating cash flow and may become more pronounced if acquisition integration requires additional spending.
  • Leverage increased substantially to fund the acquisition. Long-term debt rose to approximately $2.01 billion from $993.1 million in Q1 2026, while total debt and lease obligations reached about $2.06 billion. After subtracting cash, estimated net debt was approximately $1.98 billion, creating greater financial risk for shareholders.
  • Higher financing costs are pressuring earnings. Interest expense reached approximately $13.9 million in Q1 2027, compared with $10.2 million in Q1 2026. Cash interest paid was $11.4 million, meaning continued elevated rates or further borrowing could reduce the cash available for dividends, debt repayment and shareholder returns.

Overall, PBH continues to produce recurring profits and meaningful operating cash flow, but the latest quarter reflects a weaker margin profile and a much more leveraged capital structure. The most important issues for investors are whether the acquisition can restore revenue growth, whether management can recover gross and operating margins, and how quickly the company can reduce its newly expanded debt burden.

08/30/26 05:21 AM ETAI Generated. May Contain Errors.

Prestige Consumer Healthcare Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Prestige Consumer Healthcare's fiscal year ends in March. Their fiscal year 2026 ended on March 31, 2026.

Prestige Consumer Healthcare's net income appears to be on an upward trend, with a most recent value of $190.30 million in 2026, rising from $99.91 million in 2016. The previous period was $214.61 million in 2025. See Prestige Consumer Healthcare's forecast for analyst expectations on what's next for the company.

Prestige Consumer Healthcare's total operating income in 2026 was $309.41 million, based on the following breakdown:
  • Total Gross Profit: $595.58 million
  • Total Operating Expenses: $286.17 million

Over the last 10 years, Prestige Consumer Healthcare's total revenue changed from $806.25 million in 2016 to $1.09 billion in 2026, a change of 35.0%.

Prestige Consumer Healthcare's total liabilities were at $1.61 billion at the end of 2026, a 2.5% increase from 2025, and a 27.1% decrease since 2016.

In the past 10 years, Prestige Consumer Healthcare's cash and equivalents has ranged from $27.19 million in 2022 to $97.88 million in 2025, and is currently $63.87 million as of their latest financial filing in 2026.

Over the last 10 years, Prestige Consumer Healthcare's book value per share changed from 14.11 in 2016 to 39.89 in 2026, a change of 182.7%.


Related Companies

Financial statements for NYSE:PBH last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Leading AI Insider Issues Urgent Market Warning
A leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...
TradeSmith | Sponsoredtc pixel
Buy this stock today
Most tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...
Chaikin Analytics | Sponsoredtc pixel
Hormuz tanker traffic collapses as the oil crisis deepens
Tanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG c...
Golden Portfolio | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...
Eagle Publishing | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel